American Society for Clinical Oncology (ASCO) GI

Preliminary Results From a Randomized, Open-Label, Phase 2 Study of BotensilimabWith or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases